VCYT
Veracyte, Inc.
$44.02
-1.21
(-2.68%)
Mkt Cap
3.48B
Volume
909,616
52W Range
29.455-60.91
Sector
Healthcare
Beta
1.95
EPS (TTM)
1.44 USD
P/E Ratio
30.25
Revenue (TTM)
561.90M USD
Rev Growth (5Y)
+34.5%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$50.83
Fair Value
weak signal
14.3% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.14M | 445.76M | 361.05M | 296.54M | 219.51M | 117.48M | 120.37M | 92.01M | 71.95M | 65.08M | 49.50M | 38.19M |
| Net Income | 66.35M | 24.14M | (74.40M) | (36.56M) | (75.56M) | (34.91M) | (12.60M) | (23.00M) | (31.00M) | (31.36M) | (33.70M) | (29.37M) |
| EPS | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 | -1.30 | -1.36 |
| Free Cash Flow | 126.63M | 63.81M | 34.26M | (1.01M) | (37.00M) | (12.55M) | (5.99M) | (15.39M) | (25.67M) | (32.19M) | (33.13M) | (29.66M) |
| FCF / Share | 1.61 | 0.83 | 0.47 | -0.01 | -0.54 | -0.24 | -0.13 | -0.42 | -0.76 | -1.12 | -1.28 | -1.37 |
| Operating CF | 136.31M | 75.10M | 44.22M | 7.54M | (31.62M) | (9.71M) | (3.23M) | (13.52M) | (23.91M) | (27.98M) | (26.96M) | (27.63M) |
| Total Assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M | 120.64M | 78.67M | 101.03M | 75.28M | 64.84M |
| Total Debt | 39.65M | 50.74M | 12.63M | 14.72M | 18.85M | 12.32M | 13.61M | 25.28M | 25.25M | 25.52M | 5.03M | 4.92M |
| Cash & Equiv | 362.58M | 239.09M | 216.45M | 154.25M | 173.20M | 349.36M | 159.32M | 78.00M | 33.89M | 59.22M | 39.08M | 35.01M |
| Book Value | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M | 79.75M | 37.23M | 59.58M | 51.25M | 41.37M |
| Return on Equity | 0.05 | 0.02 | -0.07 | -0.03 | -0.07 | -0.08 | -0.05 | -0.29 | -0.83 | -0.53 | -0.66 | -0.71 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150.32M | 139.07M | 140.64M | 131.87M | 130.16M | 114.47M | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M | 90.11M |
| Net Income | 25.49M | 28.71M | 41.15M | 19.14M | (980,000) | 7.05M | 5.11M | 15.15M | 5.73M | (1.86M) | (28.29M) | (29.62M) |
| EPS | 0.32 | 0.36 | 0.52 | 0.24 | -0.01 | 0.09 | 0.07 | 0.20 | 0.07 | -0.02 | -0.39 | -0.41 |
| Free Cash Flow | 42.97M | 32.25M | 48.27M | 41.97M | 32.32M | 3.54M | 20.38M | 27.72M | 26.80M | (11.10M) | 13.05M | 11.37M |
| FCF / Share | 0.54 | 0.41 | 0.61 | 0.53 | 0.41 | 0.05 | 0.26 | 0.36 | 0.35 | -0.15 | 0.18 | 0.16 |
| Operating CF | 45.83M | 35.22M | 52.58M | 44.76M | 33.60M | 5.36M | 24.52M | 29.96M | 29.57M | (8.97M) | 15.55M | 14.17M |
| Total Assets | 1.49B | 1.44B | 1.41B | 1.37B | 1.34B | 1.32B | 1.30B | 1.28B | 1.23B | 1.20B | 1.11B | 1.12B |
| Total Debt | 40.11M | 39.33M | 39.65M | 40.45M | 50.65M | 50.50M | 50.74M | 19.69M | 20.74M | 14.04M | 12.63M | 13.73M |
| Cash & Equiv | 299.52M | 263.14M | 362.58M | 315.57M | 219.50M | 186.12M | 239.09M | 274.08M | 235.91M | 209.19M | 216.45M | 202.46M |
| Book Value | 1.39B | 1.34B | 1.31B | 1.26B | 1.22B | 1.19B | 1.18B | 1.18B | 1.13B | 1.12B | 1.04B | 1.05B |
| Return on Equity | 0.02 | 0.02 | 0.03 | 0.02 | -0.00 | 0.01 | 0.00 | 0.01 | 0.01 | -0.00 | -0.03 | -0.03 |
VCYT News
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
Veracyte (NASDAQ:VCYT) Insider John Leite Sells 4,015 Shares
Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT
Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Concurrent Investment Advisors LLC Takes Position in Veracyte, Inc. $VCYT
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors